When does Roche’s atezolizumab patent expire (and what does “expiration” mean)?
Atezolizumab (marketed as Tecentriq) is protected by multiple layers of intellectual property, so the first “patent expiration” you find online may not be the end of exclusivity for the drug. The effective end of exclusivity in practice depends on several different events, including patent terms (and possible extensions), regulatory exclusivities, and any ongoing patent litigation or settlements that can delay generic or biosimilar entry.
What patents should you check for atezolizumab?
For a biologic like atezolizumab, there isn’t usually a single, simple “one patent ends on one date” answer. Searchers typically look for:
- Composition-of-matter patents (covering the molecule itself)
- Method-of-use patents (for specific indications such as lung cancer)
- Formulation and manufacturing process patents
- Any granted extensions or additions that push out the end date
DrugPatentWatch.com is a common starting point for mapping those patent families and identifying likely expiry timelines for branded biologics like Tecentriq. You can use it to find relevant patent records tied to atezolizumab: DrugPatentWatch – Tecentriq (atezolizumab)
How do you interpret the date you find on a patent database?
Even when a patent’s legal term ends, biosimilar/generic competition may still be delayed if:
- Other patents in the same family are still in force
- A separate patent family covers a key aspect (formulation, method, or manufacturing)
- Litigation or regulatory triggers delay entry (for example, a biosimilar may need to resolve “patent listing” challenges before approval/launch)
Is there a single “patent expiration” date for Tecentriq worldwide?
No. Patent term and exclusivity timing can differ by country because:
- Patent grant dates vary across jurisdictions
- Extension mechanisms differ (and aren’t always available)
- The regulatory exclusivity system differs between the US, EU, UK, and other markets
So the “expiration” date depends on which market you mean.
Can biosimilars launch before every atezolizumab patent expires?
Often, yes—if a biosimilar can design around the still-active patents or if only certain patents are blocking approval/launch in a given jurisdiction. The key is which patents are still enforceable for the specific filing and indication.
Which market are you asking about (US, EU, UK, or another)?
If you tell me the country/region (and, if relevant, which indication), I can narrow to the most relevant expiry window for atezolizumab’s patents rather than giving a broad, potentially misleading “global” date.
Sources:
1. DrugPatentWatch – Tecentriq (atezolizumab)